Clinical efficacy and safety of bilastine. Part II Review article
Article Sidebar
Main Article Content
Abstract
Histamine is the most important mediator of an allergic reaction. Its function is revealed by acting on H1 receptor. As a result of antigen–antibody reaction, histamine is released from mastocytes and stimulates H1 receptors. This reaction largely determines symptoms of allergic rhinitis, urticaria, food allergy, asthma and atopic dermatitis. The key role of histamine in the development of an allergic reaction causes H1 blockers (antihistamines) are the primary medications for the treatment of allergic diseases. The mechanism of action of antihistamines is based on their competitive and reversible association with H1 receptors, which reduces the action of histamine as an inflammatory mediator.
Bilastine is a second generation H1 antihistamine and has antihistamine and antiallergic properties. It has a high specificity for H1 receptors and negligible affinity for other receptors (H2, H3, H4). Bilastine has a rapid onset of action and a long duration of action.
The presented study presents meta-analyses evaluating the efficacy and safety of bilastine. Bilastine as an effective and safe second generation antihistamine plays an important role in the treatment of allergic diseases. It is recommended and registered for the treatment of urticaria.
Downloads
Article Details
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Nguyen V, Simon L, Jaqua E. Allergic Dermatoses. Prim Care. 2016; 43: 433-49.
3. Fine LM, Bernstein JA. Guideline of Chronic Urticaria Beyond. Allergy Asthma Immunol Res. 2016; 8: 396-403.
4. Church MK, Weller K, Stock P et al. Chronic spontaneous urticaria in children: Itching for insight. Pediatr Allergy Immunol. 2011; 22: 1-8.
5. Raciborski F, Kłak A, Czarnecka-Operacz M et al. Epidemiology of urticaria in Poland – nationally representative survey results. Adv Dermatol Allergol. 2018; XXXV(1): 67-73.
6. Leceta A, García A, Sologuren A et al. Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions. Drugs Context. 2021; 10: 2021-5-1.
7. Xue X, Wang Q, Yang X et al. Effect of Bilastine on Chronic Urticaria: A Systematic Review and Meta-Analysis. Int Arch Allergy Immunol. 2022: 1-10.
8. Zuberbier T, Aberer W, Asero R et al. Wytyczne EAACI/GA- 2LEN/EDF/WAO dotyczące definicji, klasyfikacji, diagnostyki i leczenia pokrzywki. Alergologia Polska – Polish Journal of Allergology. 2020; 7(1): 1-28.
9. Krause K, Spohr A, Zuberbier T et al. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy. 2013; 68(7): 921-8.
10. Weller K, Church MK, Hawro T et al. Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: a real-life study. Allergy. 2018; 73(10): 2073-5.
11. Church MK, Tiongco-Recto M, Ridolo E et al. Bilastine: a lifetime companion for the treatment of allergies. Curr Med Res Opin. 2020; 36(3): 445-54.
12. Lynde CW, Sussman G, Dion PL et al. Multidisciplinary Real-World Experience With Bilastine, a Second Generation Antihistamine. J Drugs Dermatol. 2020; 19(2): 145-54.
13. Singh Randhawa A, Mohd Noor N, Md Daud MK et al. Efficacy and Safety of Bilastine in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis. Front Pharmacol. 2022; 12: 731201.
14. Sologuren A, Vinas R, Cordon E et al. Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria. Allergy Asthma Proc. 2018; 39(4): 299-304.